Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis
Authors:
- Jian XuJXJian Xu
- Si-Yang LiSLSi-Yang Li
- Deepak V. AlmeidaDADeepak V. Almeida
- Rokeya TasneenRTRokeya Tasneen
- Kala Barnes-BoyleKBKala Barnes-Boyle
- Paul J. ConversePCPaul J. Converse
- Anna M. UptonAUAnna M. Upton
- Khisimuzi MdluliKMKhisimuzi Mdluli
- Nader FotouhiNFNader Fotouhi
- Eric L. NuermbergerENEric L. Nuermberger
Preprint
Abstract
Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen) or moxifloxacin and pyrazinamide (BPaMZ regimen) shorten the treatment duration needed to cure TB in BALB/c mice compared to the first-line regimen and have yielded promising results in initial clinical trials. However, the independent contribution of the investigational new drug pretomanid to the efficacy of BPaMZ has not been examined and its contribution to BPaL has been examined only over the first 2 months of treatment. In the present study, the addition of pretomanid to BL increased bactericidal activity, prevented emergence of bedaquiline resistance, and shortened the duration needed to prevent relapse with drug-susceptible isolates by at least 2 months in BALB/c mice. Addition of pretomanid to BMZ resulted in a 1 log 10 greater CFU reduction after 1 month of treatment and/or reduced the number of mice relapsing in each of 2 experiments in BALB/c mice and in immunocompromised nude mice. Bedaquiline-resistant isolates were found at relapse in only one BMZ-treated nude mouse. Treatment of infection with a pyrazinamide-resistant mutant in BALB/c mice with BPaMZ prevented selection of bedaquiline-resistant mutants and reduced the proportion of mice relapsing compared to BMZ alone. Among severely ill C3HeB/FeJ mice with caseous pneumonia and cavitation, BPaMZ increased median survival (≥60 vs. 21 days) and reduced median lung CFU by 2.4 log 10 at 1 month compared to BMZ. In conclusion, in 3 different mouse models, pretomanid contributed significantly to the efficacy of the BPaMZ and BPaL regimens, including restricting the selection of bedaquiline-resistant mutants.Keywords
All Related Versions
- Published version: Antimicrobial Agents and Chemotherapy, 63 (5), e00021-19.
This publication has 30 references indexed in Scilit:
- Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapiesThe Lancet Infectious Diseases, 2018
- Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2017
- Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2016
- Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisThe Lancet, 2015
- Contribution of the Nitroimidazoles PA-824 and TBA-354 to the Activity of Novel Regimens in Murine Models of TuberculosisAntimicrobial Agents and Chemotherapy, 2015
- Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO ReleaseScience, 2008
- Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2008
- A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosisNature, 2000